158,537 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Purchased by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 158,537 shares of the company's stock, valued at approximately $338,000. XTX Topco Ltd owned 0.08% of Allogene Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Invesco Ltd. raised its stake in Allogene Therapeutics by 7.0% during the 4th quarter. Invesco Ltd. now owns 127,486 shares of the company's stock valued at $272,000 after acquiring an additional 8,359 shares during the last quarter. Nordea Investment Management AB increased its stake in Allogene Therapeutics by 2.1% in the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company's stock valued at $986,000 after buying an additional 9,635 shares during the period. Teacher Retirement System of Texas increased its stake in Allogene Therapeutics by 28.9% in the 4th quarter. Teacher Retirement System of Texas now owns 43,877 shares of the company's stock valued at $93,000 after buying an additional 9,839 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Allogene Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,188,838 shares of the company's stock worth $2,532,000 after acquiring an additional 9,990 shares during the period. Finally, Cibc World Markets Corp purchased a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $26,000. Institutional investors and hedge funds own 83.63% of the company's stock.

Allogene Therapeutics Trading Up 0.3 %

Shares of ALLO traded up $0.01 during midday trading on Tuesday, hitting $1.58. The stock had a trading volume of 288,776 shares, compared to its average volume of 3,192,193. Allogene Therapeutics, Inc. has a fifty-two week low of $1.23 and a fifty-two week high of $3.78. The business has a 50-day simple moving average of $1.68 and a two-hundred day simple moving average of $2.04. The firm has a market cap of $342.19 million, a P/E ratio of -1.02 and a beta of 0.99.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. On average, analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALLO has been the subject of several analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target on the stock in a research note on Friday, March 14th. Canaccord Genuity Group reiterated a "buy" rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, HC Wainwright decreased their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Allogene Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.29.

Insider Activity

In other Allogene Therapeutics news, insider Timothy L. Moore sold 14,746 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the sale, the insider now owns 250,713 shares of the company's stock, valued at $428,719.23. The trade was a 5.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David D. Chang sold 46,668 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $1.96, for a total transaction of $91,469.28. Following the transaction, the chief executive officer now directly owns 5,276,569 shares of the company's stock, valued at $10,342,075.24. The trade was a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 87,268 shares of company stock valued at $159,584 over the last 90 days. 24.30% of the stock is currently owned by company insiders.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).